EHN submitted its views on the European Commission’s public consultation aimed at evaluating the existing general pharmaceutical legislation on medicines for human use to support its revision to ensure a future-proof and crisis-resistant medicines regulatory system.
EHN’s input calls for modernising the regulatory framework to foster patient-centered innovation for cardiovascular patients. It builds on previous EHN contributions and calls in the Blueprint for EU Action on CVD.